
    
      The purpose of this study is to determine, in obese insulin resistant subjects, the effect of
      maraviroc therapy, a selective antagonist of the human chemokine receptor CCR5, on:

        1. Plasma triglyceride concentration

        2. Plasma HDL-cholesterol and LDL-cholesterol concentrations

        3. Plasma markers of cardiometabolic risk and inflammation
    
  